Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review.

The present review provides for the first time a systematic summary of evidence about the possible use of pazopanib as first-line treatment for nccRCC, with a favorable outcome despite the low strength of evidence. Pazopanib could be considered as a possible therapeutic option in this setting.